Petros Galanakis’ Post

AstraZeneca counts to biggest companies in #PHARMA industry and I am happy that it started to talk INDUSTRY 5.0. I do believe that PASCAL SORION, the new CEO will insist on the implementation of INDUSTRY 5.0 principles into the company policy and development framework and I would be happy if the membership in the INDUSTRY 5.0 STRATEGIC ALLIANCE will be part of the journey. INDUSTRY 5.0 AMBASSADORS NETWORK Industry 5.0

AstraZeneca CEO, Pascal Soriot, is investing £650 million ($827 million) in the UK, according to Chancellor Jeremy Hunt. The investment will be divided into two tranches: £450 million will go to AZ's manufacturing site in Speke, Liverpool to build out the company's R&D and manufacturing capabilities for vaccines, and the remaining £200 million will be used to expand AZ's presence near its global headquarters in Cambridge. The investment is contingent upon mutual agreement with the UK government, undisclosed "third parties," and regulatory clearance. Soriot said in a statement that the investment would enhance the UK's pandemic preparedness and demonstrate confidence in UK life sciences. The investment will help the Liverpool site respond to the threat of future pandemics and meet the growing demand for vaccines. The exact vaccines to be made there will be determined as the company's pipeline progresses. As for the Cambridge site, it will primarily support commercial and regular business operations. The investment comes about a year after Soriot blamed the UK's "discouraging" tax rate for building a $400 million active pharmaceutical ingredient facility in Ireland at the Alexion campus in Dublin. Nevertheless, the UK remains AZ's home base, with the drugmaker opening its flagship £1 billion R&D site in Cambridge last year. #astrazeneca #vaccines #vaccinedevelopment #pandemic #pharmacist #trainer

I had a stunning career spanning more than 20 years at AstraZeneca. For me, it was a game of two halves (as they say in football speak). The first half began with ICI Pharmaceuticals UK as a medical rep which then became Zeneca (when it was de-merged from ICI). We had to create a new brand that nobody ever heard of before. This was followed by the second half with a decade that began in 1999 with the merger with Astra to create AstraZeneca. The culture changed overnight. The first half saw me in the UK business. I had spent ten years with a smaller pharma company in the UK business before ICI. After 20 years of selling and launching new products and numerous new indications in the UK NHS, I was itching to move into the International business. The UK GM lost his job. In the eyes of a new senior leadership team, the door opened for me to move into international. It was wonderful. I realised how narrow the view was when working with the UK affiliate. I moved to global manufacturing in the Supply Chain & Logistics business followed by Programme Management across 18 European Affiliates. My vision took on a longer, broader focus on the business landscape. I worked with inspirational leaders (many were Swedish that I admired and they respected my ability to deliver results and deliver the numbers). In my final seven years, I headed up 18 countries in the MEA region with full P&L accountability via 8 GMs and 2 Finance and Logistics Managers based in those markets. When I saw this announcement, NOTHING surprised me. As a senior black book leader, I was accustomed to being stretched to the boundaries of my capabilities and then stretched beyond some more! We were great at setting ambition and what stood us out from the other Big Pharma was that we went on to deliver those ambitions. We did not take lightweight passengers. Those on the bus were there for a purpose, and they HAD to deliver these ambitions. AZ will deliver this ambition to be $80bn in revenue by 2030. It would put them as the first $200bn valuation company ahead of Shell. My VP International who reported to the CEO spoke in his French Corsican accent all the time how "We need to set and deliver zee ambeeshon" as I kicked off my business review presentation of my markets at Stanhope Gate when the MEA region was presenting. He was forensic with the numbers. That is probably where I learnt my master craft. I was taught to be cautious, with a risk-assessed approach allied to ambitious numbers. He tested my thinking for rigour, he drilled hard, and the thinking had to be cohesive and thorough. But that's what it takes to deliver and exceed the P&L for seven successive years with ambitious targets. If that same focus and rigour are still present, these ambitions can and will be realised. The share price last week exceeded £121 per share! What a pity that the UK government has slapped a huge Capital Gains Tax on me when I sell shares each year from my considerable holding.

What’s meaningful to my work here at AstraZeneca? Beyond our dedication to advancing healthcare in Vietnam and ensuring equitable access to the latest and most effective treatments over our 30-year presence in the country, it is the meaningful collaboration and mutual trust we nurture with our stakeholders and partners that truly stand out. On September 30, 2024, I had the privilege of meeting with Vice Minister of the Ministry of Health, Mr. Do Xuan Tuyen, to discuss our ongoing and future contributions to Vietnam’s healthcare landscape. During this meeting, we outlined AstraZeneca Vietnam's key activities in: 💡Pharmaceutical Research and Development 💡Technology Transfer Projects aimed at producing advanced drugs locally. 💡Community Investment Programs aimed at creating an equitable and sustainable healthcare system, enhancing Vietnamese patients' access to advanced medications and treatments. We reaffirmed our alignment with Vietnam’s National Strategy for Pharmaceutical Industry Development and the National Program for Domestic Pharmaceutical Production by 2030, with a vision extending to 2045. Our goal is to support Vietnam in becoming a central hub for producing original brand-name drugs in the ASEAN region. Vice Minister Do Xuan Tuyen expressed high appreciation for AstraZeneca’s contributions and support over the years, particularly during the Covid-19 pandemic. He acknowledged our efforts in technology transfer, clinical trials, disease prevention and control, and our commitment to building a sustainable healthcare system. I felt both supported and encouraged after our discussion. With continued collaboration and support from the Ministry of Health, I am confident that we can achieve remarkable outcomes that benefit our people, society, and the planet. Picture below was taken with Vice Minister Do Xuan Tuyen in Hanoi. More information in Vietnamese: https://lnkd.in/gUH-auz3

AstraZeneca India continues to advance its mission of transforming the future of healthcare by unlocking the power of science. The company's commitment to innovation is reflected in its strong pipeline progress, reinforcing its position as a key player in the healthcare industry.   Recently, AstraZeneca unveiled its new Bold Ambition during the Global Investor’s Day setting the stage for 2030! Aspiring to be pioneers in science, focused on transform patient outcomes, by 2030, globally we will deliver 20 new medicines, industry leading growth and aim to be carbon negative.   In India, we have recently announced our financial results for FY 2023-24 with 29% growth in revenue, which is one of our strongest years of performance. We owe this our talented, committed and passionate group of employees who go above and beyond in terms of achieving greater milestones every single day to transform the lives of patients. Proud to be part of a company that is unlocking the power of what science can do for people, society and the planet.   Read more here: https://lnkd.in/gtJHuUeK   #ScienceCan #AZProud

clearly a successful merger back in 1999 -

Collaboration for a Healthier Future! AstraZeneca Pharma India Ltd and Mankind Pharma join forces to enhance access to vital asthma medication in India. Together, INDIA is making strides in healthcare. Stay tuned for more updates and photos from this exciting venture on our LinkedIn page! #pharmacollaboration #healthcareinnovation

Case Study 4: Covishield-Unveiling the Truth: AstraZeneca's Vaccine Side Effects In this video, we delve into AstraZeneca's recent admission regarding the rare side effects of its Covid-19 vaccine, backed by reported news and legal documents. Stay informed as we examine the latest developments and implications surrounding this crucial topic. Don't forget to like and share this video to spread awareness. Stay tuned for an in-depth exploration! #AstraZeneca #Covid19Vaccine #SideEffects #NewsUpdate #Onpharma

(Bloomberg) -- Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Most Read from Bloomberg Biden Set to Impose Tariffs on China EVs, Strategic Sectors Ackman Scolded Over DEI Views at Closed-Door Milken Session Apple Apologizes for iPad Pro Ad, Scraps Plan to Air It on TV Marjorie Taylor Greene Finally Got What She Deserved: Defeat ‘Seriously Underwater’ Home Mortgages Tick Up Across the US Novavax will receive $500 million in upfront payments as well as $700 million if all development, regulatory and launch milestones are met, according to a statement Friday. Novavax, which will receive tiered royalties on any vaccine sales, said Sanofi is also taking a minority equity stake of about 5% in the US company. Novavax shares surged as much as 217% in premarket trading before paring those gains to about 130%. If the jumps holds through Friday’s trading session it will be the stock’s biggest one-day increase on record. The pact links two big players in the vaccine world that both missed out on the rush to develop and commercialize Covid shots quickly during the pandemic. Amid various setbacks, Sanofi and Novavax ceded tens of billions of dollars in sales to nimbler messenger-RNA developers including the Pfizer-BioNTech alliance and Moderna Inc. Now, Sanofi will have the rights to drive sales of Novavax’s Covid-19 shot worldwide from next year, except for in India, Japan and South Korea, where Novavax already has advance purchasing agreements. The French drugmaker also has the sole license to use Novavax’s protein-based Covid shot in combination with its flu shot, which it said will offer patients “enhanced convenience and protection against two serious respiratory viruses.” https://lnkd.in/ghZ3VzwD

“The #CEIVPharma programme is a trusted mark of quality and excellence in the handling of #pharmaceuticals, with hundreds of companies globally across the supply chain, including airlines, ground handling service providers and freight forwarders, achieving certification. This initiative between Pharma.Aero and IATA underscores the continuous commitment to not just maintain but elevate CEIV Pharma certification. Extensive dialogue with stakeholders has been instrumental in new identifying opportunities for the programme such as reaching smaller enterprises and better serving underserved markets as well as process enhancements,” said Frederic Leger, International Air Transport Association (IATA) senior vice president of commercial products and services. Trevor Caswell, chairman of Pharma.Aero, lauded the collective efforts of #PharmaAero members participating in the 2-year project. “As a leading advocate for excellence in pharmaceutical logistics, Pharma.Aero leverages the collective expertise of our global community to drive innovation and best practices in the industry. We commend all our members for their time and dedication to this project. Their contributions were decisive in getting first-hand experiences to accurately assess the CEIV Pharma certification and identify opportunities for enhancement”, said Caswell. “Together, as Pharma.Aero, we are driving positive change in pharmaceutical logistics to better serve the needs of patients globally”, concluded Trevor Caswell. #PharmaAero #IATA #CEIVPharma #Pharmaceuticals #AirCargo #InternationalAirTransportAssociation #Partnership #SupplyChain #Logistics #PharmaHandling #Healthcare #PharmaSafety